Thyrotropin receptor antibodies (TRAbs) play a significant role in the course of hepatic dysfunction (HDF) in patients with Graves’ disease (GD). However, few studies have considered the factors that influence the relationships among TRAbs, thyroid hormone levels, and hepatic function in subjects with newly diagnosed GD. Here we investigated the associations of TRAbs with thyroid hormones and hepatic function and assessed potential factors that can influence these associations among patients with GD. A total of 368 patients newly diagnosed with GD were collected in this cross-sectional study. Patients who had received antithyroid drugs, radioactive iodine, or surgery were excluded. Levels of TRAbs and thyroid hormones and hepatic function were recorded. Linear and binary logistic regression analysis models were applied to investigate associations among these variables after adjusting for confounding characteristics. There was a significant difference in TRAbs indices between the HDF and normal hepatic function groups (p <0.05). After adjusting for confounders, the relationship between TRAbs and thyroid hormones was nonlinear, showing a curve with an initial positive slope and a subsequent flattening (p <0.05). Higher TRAbs were associated with HDF [odds ratio (OR) 1.036, 95% confidence interval (CI) 1.018–1.053 per 1-IU/l increase]. These associations were modified by age, but not by gender, smoking status, Graves’ orbitopathy, thyroid-peroxidase antibody levels, or thyroglobulin antibody levels. In younger patients, increasing TRAbs were correlated with higher thyroid hormones and HDF (OR 1.034, 95% CI 1.017–1.052) per1-IU/l increase). In older patients, TRAbs were not correlated with thyroid hormones or HDF (OR 1.024, 95% CI 0.993–1.056) per 1-IU/l increase. Age can affect the impact of TRAbs on thyroid hormone levels and hepatic function in GD. TRAb measurement can have good predictive value in younger patients.

中文翻译：

---

年龄可调节​​ TRAb 对格雷夫斯病患者甲状腺激素和肝功能的影响

促甲状腺激素受体抗体 (TRAb) 在格雷夫斯病 (GD) 患者的肝功能障碍 (HDF) 过程中发挥重要作用。然而，很少有研究考虑影响新诊断 GD 受试者 TRAbs、甲状腺激素水平和肝功能之间关系的因素。在这里，我们调查了 TRAb 与甲状腺激素和肝功能的关联，并评估了可能影响 GD 患者这些关联的潜在因素。该横断面研究共收集了 368 名新诊断为 GD 的患者。接受过抗甲状腺药物、放射性碘或手术的患者被排除在外。记录 TRAb 和甲状腺激素的水平以及肝功能。在调整混杂特征后，应用线性和二元逻辑回归分析模型来研究这些变量之间的关联。HDF 组和正常肝功能组之间的 TRAbs 指数存在显着差异（p <0.05）。调整混杂因素后，TRAbs 和甲状腺激素之间的关系是非线性的，显示曲线具有初始正斜率和随后变平（p <0.05）。较高的 TRAb 与 HDF 相关 [优势比 (OR) 1.036，95% 置信区间 (CI) 每增加 1-IU/l 为 1.018–1.053]。这些关联受年龄的影响，但不受性别、吸烟状况、格雷夫斯眼眶病、甲状腺过氧化物酶抗体水平或甲状腺球蛋白抗体水平的影响。在年轻患者中，增加的 TRAb 与较高的甲状腺激素和 HDF 相关（OR 1.034，95% CI 1.017–1.052）per1-IU/l）。在老年患者中，TRAb 与甲状腺激素或 HDF 无关（OR 1.024，95% CI 0.993–1.056）每增加 1-IU/l。年龄会影响 TRAb 对 GD 中甲状腺激素水平和肝功能的影响。TRAb 测量对年轻患者具有良好的预测价值。